[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-cancer-with-hepatic-metastase\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-cancer-with-hepatic-metastase":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100658170","hepatic-artery-infusion-pump-chemotherapy-for-liver-metastases-from-resected-pancreatic-and-duodenal-adenocarcinoma-100658170",false,"NCT07845617","Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma","Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma: A Prospective Feasibility Study","Inclusion Criteria:\n\n* Age 18-80 years\n* Histologically confirmed pancreatic or duodenal adenocarcinoma\n* Completed or currently receiving curative-intent treatment\n* Evidence of isolated or liver-dominant metastases (radiographic or clinical)\n* Deemed clinically eligible for hepatic artery infusion pump (HAIP) placement and floxuridine (FUDR)-based chemotherapy by a multidisciplinary oncology team\n* Scheduled for HAIP placement at AdventHealth Orlando\n\nExclusion Criteria:\n\n\\- Patients who are clinically ineligible for HAIP placement or FUDR therapy are excluded","ALL","18 Years","80 Years",{"count":20,"type":21},10,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant metastases after surgery and systemic chemotherapy. The main questions it aims to answer are:\n\nDoes HAIP chemotherapy improve liver tumor response based on imaging criteria (RECIST)? What are the progression-free survival and overall survival outcomes in this patient population?\n\nParticipants will:\n\nUndergo placement of a hepatic artery infusion pump as part of standard clinical care Receive floxuridine (FUDR)-based chemotherapy through the pump Have clinical data, imaging results, and laboratory markers (e.g., ctDNA, CEA, CA 19-9) collected from their medical records over time",[26,27,28,29,30],"Pancreas Cancer With Hepatic Metastase","Pancreas Adenocarcinoma","Duodenal Cancer","Duodenal Adenocarcinoma","Ampullary Adenocarcinoma",[32,33,34,35,36,37],"Pancreas cancer","Pancreas adenocarcinoma","Duodenal cancer","Liver metastases","Ampullary cancer","Ampullary adenocarcinoma","RECRUITING","2026-09-25",{"date":41,"type":42},"2026-09-29","ACTUAL",{"date":44,"type":21},"2026-11-01",{"date":46,"type":21},"2028-05-02",{"name":48,"class":49},"AdventHealth","OTHER"]